Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Jun 15 2013

Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet™, a delayed-release formulation of generic metformin, at the 73^rd Scientific Sessions of the American Diabetes Association in Chicago, IL. Dr. DeFronzo, Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial Veterans Administration Hospital, will describe the results of Elcelyx's Phase 2a clinical trial that compared NewMet with generic metformin in patients with Type 2 diabetes. Mark Fineman, Ph.D., Senior Vice President, Research & Development at Elcelyx will present a second poster accepted as a late-breaker that describes a model designed to predict the metformin plasma exposure with NewMet in Type 2 diabetes patients with mild, moderate and severe renal impairment.

The schedule for the NewMet poster presentations at the McCormick Place Convention Center follows:

Dissociation between metformin plasma exposure and its glucose-lowering effect: A novel gut-mediated mechanism of action

• Date and Time: Sunday, June 23, 2013, 12:00 p.m. to 2:00 p.m. CT
• Category: 01-D Clinical Therapeutics/New Technology – Oral Agents
• Poster #:  1087-P
• Presenter:  Ralph A. DeFronzo, M.D., University of Texas Health Science Center, San Antonio

Delayed-release metformin may be suitable for use in diabetes patients with renal impairment that are contraindicated for currently available metformin formulations

• Date and Time: Sunday, June 23, 2013, 12:00 p.m. to 2:00 p.m. CT
• Category: 01-D Clinical Therapeutics/New Technology – Oral Agents
• Poster #:  75-LB
• Presenter:  Mark Fineman, Ph.D., Elcelyx Therapeutics 

SOURCE Elcelyx Therapeutics